Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an announcement.
Medicenna Therapeutics has appointed veteran oncology drug developer Dr. Nageatte Ibrahim as Chief Medical Officer in a fractional role, drawing on her extensive experience at Innovent Biologics, Merck, GSK, and leading academic institutions to guide its superkine-based immunotherapy programs. The hire is expected to bolster the company’s global clinical development capabilities as it advances IL-2 superagonist candidates MDNA11 and MDNA113 and builds on evidence of efficacy for bizaxofusp in glioblastoma, potentially strengthening its competitive position in next-generation immuno-oncology.
Dr. Ibrahim, who played a key leadership role in the development and registration of pembrolizumab and other landmark oncology therapies across multiple tumor types, brings a track record of running pivotal studies and tumor-agnostic approvals that could accelerate Medicenna’s trials and regulatory strategies. Her background in building high-performing clinical teams and shaping U.S. oncology operations is likely to aid Medicenna’s efforts to expand its clinical pipeline, optimize trial design in solid tumors, and better address unmet needs in difficult-to-treat cancers such as melanoma and glioblastoma.
The most recent analyst rating on (TSE:MDNA) stock is a Sell with a C$0.59 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on MDNA Stock
According to Spark, TipRanks’ AI Analyst, MDNA is a Neutral.
The score is primarily weighed down by weak financial performance (pre-revenue, ongoing losses and negative free cash flow with shrinking equity/assets) and bearish technicals (below major moving averages with negative momentum). Valuation is also constrained by the negative P/E and lack of dividend support.
To see Spark’s full report on MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company developing novel Superkines, including highly selective IL-2, IL-4, and IL-13 variants, as well as first-in-class Empowered Superkines for cancer and autoimmune diseases. Its pipeline features MDNA11, a long-acting IL-2 superagonist designed to preferentially activate cancer-killing effector T cells and NK cells, and MDNA113, a targeted PD-1 x IL-2 bifunctional program in development for solid tumors.
Average Trading Volume: 103,021
Technical Sentiment Signal: Sell
Current Market Cap: C$44.67M
Find detailed analytics on MDNA stock on TipRanks’ Stock Analysis page.